ONC
BeOne Medicines AG (ONC) reported revenue of $5.34B for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Revenue | Change |
|---|---|---|
| FY 2025 | $5.34B | +40.2% |
| FY 2024 | $3.81B | +55.0% |
| FY 2023 | $2.46B | +73.7% |
| FY 2022 | $1.42B | +20.4% |
| FY 2021 | $1.18B | +280.8% |
| FY 2020 | $308.87M | -27.9% |
| FY 2019 | $428.21M | +116.0% |
| FY 2018 | $198.22M | -16.8% |
| FY 2017 |
BeOne Medicines AG (ONC) reported revenue of $5.34B for fiscal year 2025, as filed in its audited annual report with the SEC.
Between fiscal 2014 and fiscal 2025, BeOne Medicines AG's revenue grew from $13.04M to $5.34B.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $238.39M |
| +22179.2% |
| FY 2016 | $1.07M | -87.9% |
| FY 2015 | $8.82M | -32.4% |
| FY 2014 | $13.04M | - |